Search results

Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

Result type

Technology appraisal guidance

Published

8 May 2024

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Result type

Technology appraisal guidance

Published

18 February 2016

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

Result type

Technology appraisal guidance

Published

6 September 2017

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

Result type

Technology appraisal guidance

Published

26 April 2017

Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

Result type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

Result type

Technology appraisal guidance

Published

6 February 2018

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

25 January 2017

NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .

Result type

Medtech innovation briefing

Published

12 April 2018

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Result type

Evidence summary

Published

9 September 2014

NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

Result type

Medtech innovation briefing

Published

9 February 2017

This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

Result type

HealthTech guidance

Published

14 August 2013

Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

Result type

Technology appraisal guidance

Published

3 May 2023

Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

Result type

Technology appraisal guidance

Published

25 November 2009